Kathy Hildebrand
University of Calgary
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kathy Hildebrand.
Circulation | 2011
Todd J. Anderson; Francois Charbonneau; Lawrence M. Title; Jean Buithieu; M. Sarah Rose; Heather Conradson; Kathy Hildebrand; Marinda Fung; Subodh Verma; Eva Lonn
Background— Biomarkers of atherosclerosis may refine clinical decision making in individuals at risk of cardiovascular disease. The purpose of the study was to determine the prognostic significance of endothelial function and other vascular markers in apparently healthy men. Methods and Results— The cohort consisted of 1574 men (age, 49.4 years) free of vascular disease. Measurements included flow-mediated dilation and its microvascular stimulus, hyperemic velocity, carotid intima-media thickness, and C-reactive protein. Cox proportional hazard models evaluated the relationship between vascular markers, Framingham risk score, and time to a first composite cardiovascular end point of vascular death, revascularization, myocardial infarction, angina, and stroke. Subjects had low median Framingham risk score (7.9%). Cardiovascular events occurred in 71 subjects (111 events) over a mean follow-up of 7.2±1.7 years. Flow-mediated dilation was not associated with subsequent cardiovascular events (hazard ratio, 0.92; P=0.54). Both hyperemic velocity (hazard ratio, 0.70; 95% confidence interval, 0.54 to 0.90; P=0.006) and carotid intima-media thickness (hazard ratio, 1.45; confidence interval, 1.15 to 1.83; P=0.002) but not C-reactive protein (P=0.35) were related to events in a multivariable analysis that included Framingham risk score (per unit SD). Furthermore, the addition of hyperemic velocity to Framingham risk score resulted in a net clinical reclassification improvement of 28.7% (P<0.001) after 5 years of follow-up in the intermediate-risk group. Overall net reclassification improvement for hyperemic velocity was 6.9% (P=0.24). Conclusions— In men, hyperemic velocity, the stimulus for flow-mediated dilation, but not flow-mediated dilation itself was a significant risk marker for adverse cardiovascular outcomes. The prognostic value was additive to traditional risk factors and carotid intima-media thickness. Hyperemic velocity, a newly described marker of microvascular function, is a novel tool that may improve risk stratification of lower-risk healthy men.
Canadian Journal of Cardiology | 2009
Subodh Verma; Eva Lonn; Alykhan Nanji; Kevin Browne; Richard Ward; Annette Robertson; Heather Conradson; Kathy Hildebrand; Rollin Brant; Todd J. Anderson
BACKGROUND Plasma levels of the inflammatory biomarker C-reactive protein (CRP) predict cardiovascular risk and may represent a target for treating and/or monitoring risk-reduction strategies. The effect of angiotensin-converting enzyme inhibitors on CRP levels has not been adequately studied. METHODS A total of 264 men and women, with CRP levels of 2 mg/L or greater and no history of cardiovascular disease, were enrolled in a 12-week randomized, double-blind, placebo-controlled study. Participants were randomly assigned to receive 10 mg/day of ramipril (n=132) or placebo (n=132) for 12 weeks. The main outcome measure was the change in CRP levels from baseline to 12 weeks in the ramipril- versus placebo treated patients. RESULTS The mean (+/- SD) age was 53+/-9 years (60% men). Baseline demographics were similar between the volunteers allocated to receive either placebo or ramipril. The geometric mean CRP at baseline was 3.84 mg/L (95% CI 3.62 mg/L to 4.06 mg/L). The percentage change in geometric mean CRP values over 12 weeks was --13.2% (95% CI --22.3% to --3.2% ) in the placebo group compared with --21.1% (95% CI --29.9% to --11.2%) in the ramipril group (P nonsignificant), indicating no significant reduction in the primary end point of the trial. CONCLUSIONS A 12-week ramipril treatment protocol for healthy middle-aged volunteers did not lower CRP levels compared with placebo. However, because of the inherent variability of CRP levels, a much larger study is required to exclude a small treatment effect.
Journal of Assisted Reproduction and Genetics | 1988
Maha M. Mahadevan; Judy Fleetham; Lesley Long-Simpson; Kathy Hildebrand; Patrick J. Taylor
SummaryA preovulatory oocyte with two germinal vesicles was recovered. This oocyte underwent germinal vesicle breakdown but did not form a polar body.
JAMA | 2002
Merril L. Knudtson; D. George Wyse; P. Diane Galbraith; Rollin Brant; Kathy Hildebrand; Diana Paterson; Deborah Richardson; Connie Burkart; Ellen Burgess
Canadian Journal of Cardiology | 2003
Todd J. Anderson; Roberts Ac; Kathy Hildebrand; Heather Conradson; Charlotte Jones; Peter Bridge; Edworthy S; Eva Lonn; Subodh Verma; Francois Charbonneau
American Journal of Medical Genetics | 1986
Renée H. Martin; Kathy Hildebrand; Judy Yamamoto; Dianna Peterson; Alfred W. Rademaker; Patrick J. Taylor; C. C. Lin; John M. Opitz
Archive | 2002
Merril L. Knudtson; D. George Wyse; P. Diane Galbraith; Kathy Hildebrand; Deborah Richardson; Ellen Burgess
Circulation | 2011
Todd J. Anderson; Francois Charbonneau; Lawrence M. Title; Jean Buithieu; M. Sarah Rose; Heather Conradson; Kathy Hildebrand; Marinda Fung; Subodh Verma; Eva Lonn
Canadian Journal of Cardiology | 2014
Heather Conradson; Kathy Hildebrand
Canadian Journal of Cardiology | 2014
Kathy Hildebrand; Heather Conradson